Related Experiment Video

Updated: May 26, 2026

Evaluation of the Efficacy of the H. pylori Protein HP-NAP as a Therapeutic Tool for Treatment of Bladder Cancer in an Orthotopic Murine Model
06:12

Evaluation of the Efficacy of the H. pylori Protein HP-NAP as a Therapeutic Tool for Treatment of Bladder Cancer in an Orthotopic Murine Model

Published on: May 29, 2015

p53 status in locally advanced bladder cancer

Omer Dizdar, Umut Demirci

    Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
    |December 21, 2011
    PubMed
    Summary

    No abstract available in PubMed .

    More Related Videos

    Magnetic Resonance Imaging Assessment of Carcinogen-induced Murine Bladder Tumors
    05:19

    Magnetic Resonance Imaging Assessment of Carcinogen-induced Murine Bladder Tumors

    Published on: March 29, 2019

    Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
    11:02

    Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

    Published on: October 30, 2013

    Related Experiment Videos

    Last Updated: May 26, 2026

    Evaluation of the Efficacy of the H. pylori Protein HP-NAP as a Therapeutic Tool for Treatment of Bladder Cancer in an Orthotopic Murine Model
    06:12

    Evaluation of the Efficacy of the H. pylori Protein HP-NAP as a Therapeutic Tool for Treatment of Bladder Cancer in an Orthotopic Murine Model

    Published on: May 29, 2015

    Magnetic Resonance Imaging Assessment of Carcinogen-induced Murine Bladder Tumors
    05:19

    Magnetic Resonance Imaging Assessment of Carcinogen-induced Murine Bladder Tumors

    Published on: March 29, 2019

    Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
    11:02

    Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

    Published on: October 30, 2013

    Related Concept Videos

    Abnormal Proliferation02:23

    Abnormal Proliferation

    Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...

    Articles linked to this work by shared authors, journal, and citation graph.

    Durable Response to Sotorasib Plus Panitumumab in NRAS G12C-Mutated, Microsatellite Instability-High (MSI-H) Rectal Cancer Refractory to Immunotherapy.

    Cureus·2026

    Preimplantation genetic testing (PGT-M) awareness in BRCA-positive individuals in Türkiye: a dual physician-patient survey.

    Scientific reports·2026

    Real-World Outcomes and Progression Patterns with First-Line Osimertinib in Patients with Advanced EGFR-Mutant Non-Small Cell Lung Cancer: A Nationwide Turkish Oncology Group Study.

    Cancers·2026

    Prognostic Value of the Inflammatory Burden Index (IBI) in Metastatic Urothelial Carcinoma Prior to First-Line Therapy.

    Medicina (Kaunas, Lithuania)·2026

    The temporal evaluation of RAS mutation by liquid biopsy at progression after bevacizumab-based treatment in patients with metastatic colorectal cancer.

    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·2026

    Nutritional Indexes and Their Variations as Predictors of Atezolizumab Plus Chemotherapy Efficacy in Extensive-Stage Small Cell Lung Cancer: A Turkish Oncology Group Study.

    Journal of immunotherapy (Hagerstown, Md. : 1997)·2026

    COMBI-I: Long-Term Overall Survival With Spartalizumab Plus Dabrafenib and Trametinib in BRAF V600-Mutant Advanced Melanoma.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

    Prognostic and Predictive Effect of Age in Molecularly Defined Lower-Grade Gliomas.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

    Neoadjuvant Intralesional Daromun (L19IL2/L19TNF) in Resectable Locally Advanced Melanoma: An Update on the Efficacy and Safety Results of the PIVOTAL Phase III Trial.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

    Biomarker-Stratified Phase II Trial of Trastuzumab Rezetecan in Advanced Salivary Gland Carcinoma Across Cohorts With High and Low Human Epidermal Growth Factor Receptor 2 Expression.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

    Contemporary Management of Relapsed or Refractory Chronic Lymphocytic Leukemia.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

    Systemic Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: ASCO Living Guideline, Version 2026.1.4.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us